secwatch.observer — SEC 8-K summary
======================================

Issuer:     Oruka Therapeutics, Inc. (ORKA)
CIK:        0000907654
Form:       8-K
Filed at:   2022-12-09T23:59:59+00:00
Accession:  0000950170-22-026298
Event type: other
Sentiment:  neutral
Materiality: 0.35
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ARCA biopharma awards $100K retention bonuses and 40K RSUs each to COO Keuer and CFO Dekker
--------------------------------------------------------------------------------

- COO Thomas Keuer and CFO C. Jeffrey Dekker each receive $100,000 cash retention bonus and 40,000 RSUs.
- RSUs vest one year from December 8, 2022, subject to continued employment.
- Cash bonus payable upon earlier of a change in control or certain clinical development decisions by the Board.
- Unvested RSUs accelerate upon change in control or involuntary termination without cause or for good reason.
- Retention incentives designed to retain executives through key corporate milestones.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/907654/000095017022026298/0000950170-22-026298-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/907654/000095017022026298/abio-20221208.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-026298

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer